Skip to Main Content

Alzheimer’s

Alzheimer’s research news: Here’s the latest on Alzheimer’s disease, from research and development to policy debates on new drugs and treatments. Alzheimer’s, the most common cause of dementia, is the sixth leading cause of death in the U.S.

Latest

Pharma Allison DeAngelis

STAT Plus: Eli Lilly’s Alzheimer’s drug gets thumbs-down from European regulators

Health Elaine Chen and Katie Palmer

STAT Plus: In a first, Eli Lilly to connect patients to telehealth providers of Alzheimer’s care

Health tech Lizzy Lawrence

STAT Plus: New tests for Alzheimer’s and cancer get FDA’s ‘breakthrough’ status

Health Elizabeth Cooney

‘Simply good science’: Women’s health research reveals clues to aging and Alzheimer’s

Letters to the editor Torie Bosch

Is there an amyloid mafia? STAT readers weigh in

Letters to the editor Dennis J. Selkoe

There is no ‘amyloid cabal’ in Alzheimer’s research

First Opinion Charles Piller — Science

How the ‘amyloid mafia’ took over Alzheimer’s research

First Opinion Gabriel Waterman

‘Where are our patients?’: Three days of searching during the LA fires

All Coverage

Politics Lizzy Lawrence

STAT Plus: Federal watchdog raises some concerns about the FDA’s accelerated approval program

Morning Rounds Theresa Gaffney

Head trauma & herpes, antidepressants & breast milk, Califf & Humpty Dumpty

advertisement

Biotech Allison DeAngelis

STAT Plus: Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results

Biotech Jason Mast

STAT Plus: Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial

Biotech Andrew Joseph

STAT Plus: Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved

Adam's Take Adam Feuerstein

STAT Plus: Mild Alzheimer’s patients won’t save Cassava Sciences

Biotech Jonathan Wosen

STAT Plus: Small mid-stage trial suggests targeted magnetic pulses to brain could slow Alzheimer’s

Morning Rounds Anil Oza

Congressional races to watch, auditory hallucinations, Alzheimer’s drug data

Biotech Elaine Chen

STAT Plus: Eli Lilly says modified dosing of its Alzheimer’s drug may be safer

First Opinion Naveen Reddy and Kristine Yaffe

Blood-based biomarkers for Alzheimer’s present complex challenges to health care system

Biotech Elizabeth Cooney

STAT Plus: Amgen, Biogen and Takeda talk about R&D on tough targets

In the Lab Megan Molteni

STAT Plus: Chickenpox, shingles, Alzheimer’s? Evidence mounts for a viral cause of dementia

Morning Rounds Theresa Gaffney

Morning Rounds: Why aren’t we doing better on cardiovascular health?

Biotech Jonathan Wosen

STAT Plus: Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines

Health Jonathan Saltzman — Boston Globe

STAT Plus: ‘I’m still here’: Before Alzheimer’s, he prided himself on his intellect

Biotech Jason Mast

STAT Plus: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial

First Opinion Adina Wise

Who should get to see the neurologist first: the sick or the at-risk?

In the Lab O. Rose Broderick

Alzheimer’s drug may raise the risk of brain bleed in patients with Down syndrome

First Opinion Mike Zuendel

Phasing out the ‘D-word’

Biotech Elaine Chen

STAT Plus: Older GLP-1 drug may help protect brains of Alzheimer’s patients, early study suggests

In the Lab Associated Press

Blood tests for Alzheimer’s diagnosis were 91% accurate in new study

Лучший частный хостинг